The ZRO is a non-incisional, transcervical female sterilization device. The ZRO will compete with both traditional surgical tubal ligation and other transcervical sterilization devices. 

The ZRO has tremendous benefits over surgical tubal ligation. The ZRO procedure is minimally invasive resulting in no incisions or scars. The procedure may be easily performed in an office based setting and requires local anesthesia. The ZRO procedure lowers the likelihood of post-operative pain and reduces the recovery time to less than one day compared to three to five days or more for surgical procedures.

The total cost of the ZRO procedure is approximately half the cost of surgical tubal ligation.  The reduced recovery time also lowers overall costs associated with recovery and work loss.

The ZRO is less invasive.  While the ZRO is implanted transcervically, it is implanted at the ostium (opening) of the fallopian tube as opposed to insertion within the tube. As a result, the ZRO is superior in that it is easier for physicians to learn the insertion technique and therefore to insert the device correctly.

The ZR device surgeon adoption is estimated to well adopted by physicians due to its’ simple delivery and insertion method.

Illustration of the ZRO Implant and Insertion Method

View Video

The ZRO is manufactured with proven bio-compatible materials, as opposed to exotic  materials or thermal energy device delivery solutions. The materials comprising the ZRO have been utilized for decades in medical applications and have a known clinical history. As a result, the ZRO has a varied and more reliable source of material supplies resulting in considerably reduced manufacturing costs. In addition to reduced costs of manufacturing, the ZRO may be implanted with current hysteroscopic instrumentation and grasping devices.  Each of the other products, especially the Adiana product, requires special, costly instrumentation for implantation and activation.

This device is not FDA approved. Not for sale in the U.S.